NO20060556L - Quetiapinmetabolitt - Google Patents

Quetiapinmetabolitt

Info

Publication number
NO20060556L
NO20060556L NO20060556A NO20060556A NO20060556L NO 20060556 L NO20060556 L NO 20060556L NO 20060556 A NO20060556 A NO 20060556A NO 20060556 A NO20060556 A NO 20060556A NO 20060556 L NO20060556 L NO 20060556L
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
symptoms
bipolar
disorders
formula
Prior art date
Application number
NO20060556A
Other languages
English (en)
Norwegian (no)
Inventor
Scott W Grimm
Helen R Winter
Patricia C Davis
Raymond F Suckow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060556L publication Critical patent/NO20060556L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20060556A 2003-07-02 2006-02-02 Quetiapinmetabolitt NO20060556L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en) 2003-07-02 2004-06-28 Metabolite of quetiapine

Publications (1)

Publication Number Publication Date
NO20060556L true NO20060556L (no) 2006-04-03

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060556A NO20060556L (no) 2003-07-02 2006-02-02 Quetiapinmetabolitt

Country Status (20)

Country Link
US (1) US20050026900A1 (is)
EP (1) EP1644005B1 (is)
JP (1) JP2007516193A (is)
KR (1) KR20060082037A (is)
CN (1) CN1816339B (is)
AR (1) AR045004A1 (is)
AT (1) ATE477803T1 (is)
AU (1) AU2004253334A1 (is)
BR (1) BRPI0412127A (is)
CA (1) CA2531284A1 (is)
DE (1) DE602004028739D1 (is)
ES (1) ES2349091T3 (is)
IL (1) IL172616A0 (is)
IS (1) IS8283A (is)
MX (1) MXPA05013869A (is)
NO (1) NO20060556L (is)
RU (1) RU2005141060A (is)
TW (1) TW200509944A (is)
UY (1) UY28400A1 (is)
WO (1) WO2005002586A1 (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164155A0 (en) * 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2006113425A1 (en) * 2005-04-14 2006-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing quetiapine fumarate
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
WO2008079839A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab Compounds and uses thereof
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2008079848A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab (Se/Se) Compounds and uses thereof
WO2007062337A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Crystalline forms
US20090069292A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Liquid Formulations
CN101360725B (zh) * 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
WO2008079838A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab Compounds and uses thereof
WO2007062336A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Salt forms
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
US20100093700A1 (en) * 2007-03-22 2010-04-15 Astrazeneca Ab Methods of Treating Mood Disorders
CN102781236B (zh) 2009-12-31 2015-01-07 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
DK2544536T3 (en) 2010-03-11 2019-02-04 Kempharm Inc FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5661184A (en) * 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
AU5489299A (en) * 1998-08-18 2000-03-14 Sepracor, Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
AU2004206931A1 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease

Also Published As

Publication number Publication date
EP1644005B1 (en) 2010-08-18
IL172616A0 (en) 2006-04-10
MXPA05013869A (es) 2006-02-28
US20050026900A1 (en) 2005-02-03
JP2007516193A (ja) 2007-06-21
IS8283A (is) 2006-02-01
RU2005141060A (ru) 2006-07-27
AU2004253334A1 (en) 2005-01-13
ATE477803T1 (de) 2010-09-15
WO2005002586A8 (en) 2006-02-09
UY28400A1 (es) 2005-01-31
CN1816339A (zh) 2006-08-09
DE602004028739D1 (de) 2010-09-30
CA2531284A1 (en) 2005-01-13
BRPI0412127A (pt) 2006-08-15
WO2005002586A1 (en) 2005-01-13
AR045004A1 (es) 2005-10-12
KR20060082037A (ko) 2006-07-14
ES2349091T3 (es) 2010-12-27
EP1644005A1 (en) 2006-04-12
TW200509944A (en) 2005-03-16
CN1816339B (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
NO20060556L (no) Quetiapinmetabolitt
UY29924A1 (es) Medicamentos en base a 11-(4-(2-(2-hidroxietoxi)etil)-1-piperazinil)dibenzo-(b,f)(1,4)tiazepina y sus sales farmacéuticamente aceptables
DE60231826D1 (de) Abgabevorrichtung für arzneimittel
GT200100183A (es) Derivados de quinolina y quinazolina.
IL169358A (en) A pharmaceutical formulation containing aripiprazole or its metabolite and serotonin reuptake inhibitors for the preparation of a medication to treat mood disorders
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BR0109161A (pt) Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
NO20065732L (no) 4-Hydroksy-4-metylpiperidin-1-karboksylsyre (4-metoksy-7-morfolin-4-yl-benzotiazol-2-yl)-amid
DE60209511D1 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
BRPI0507609A (pt) combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
BRPI0813436A2 (pt) Particulados de ácido (4,6-bis (dimetilamino)-2-(4-(4-(trifluorometil) benzamido)-benzil)pirimindin-5-il} acético, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação dos particulados.
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BR0117009A (pt) Composiçoes para utilização no tratamento de distúrbios associados a ige
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
UY27018A1 (es) Derivados de la pirimidina
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
BR0212167A (pt) Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada
MY139551A (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
UY28401A1 (es) Metabolito
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
UY26742A1 (es) S-metil-dihidro-ziprasidona para el tratamiento de trastornos psiquiatricos y oculares
BR0309684A (pt) O tratamento de dor com ifendropil

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application